123 related articles for article (PubMed ID: 11142630)
1. Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
Buckheit RW; Russell JD; Xu ZQ; Flavin M
Antivir Chem Chemother; 2000 Sep; 11(5):321-7. PubMed ID: 11142630
[TBL] [Abstract][Full Text] [Related]
2. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
[TBL] [Abstract][Full Text] [Related]
3. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum.
Kashman Y; Gustafson KR; Fuller RW; Cardellina JH; McMahon JB; Currens MJ; Buckheit RW; Hughes SH; Cragg GM; Boyd MR
J Med Chem; 1992 Jul; 35(15):2735-43. PubMed ID: 1379639
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
[TBL] [Abstract][Full Text] [Related]
5. Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
Buckheit RW; Russell JD; Pallansch LA; Driscoll JS
Antivir Chem Chemother; 1999 May; 10(3):115-9. PubMed ID: 10431610
[TBL] [Abstract][Full Text] [Related]
6. Calanolides, the naturally occurring anti-HIV agents.
Xu ZQ; Flavin MT; Jenta TR
Curr Opin Drug Discov Devel; 2000 Mar; 3(2):155-66. PubMed ID: 19649847
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1.
Currens MJ; Gulakowski RJ; Mariner JM; Moran RA; Buckheit RW; Gustafson KR; McMahon JB; Boyd MR
J Pharmacol Exp Ther; 1996 Nov; 279(2):645-51. PubMed ID: 8930167
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
9. The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A.
Auwerx J; Rodríguez-Barrios F; Ceccherini-Silberstein F; San-Félix A; Velázquez S; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
Mol Pharmacol; 2005 Sep; 68(3):652-9. PubMed ID: 15961674
[TBL] [Abstract][Full Text] [Related]
10. In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
Xu ZQ; Buckheit RW; Stup TL; Flavin MT; Khilevich A; Rizzo JD; Lin L; Zembower DE
Bioorg Med Chem Lett; 1998 Aug; 8(16):2179-84. PubMed ID: 9873509
[TBL] [Abstract][Full Text] [Related]
11. Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C).
Zembower DE; Liao S; Flavin MT; Xu ZQ; Stup TL; Buckheit RW; Khilevich A; Mar AA; Sheinkman AK
J Med Chem; 1997 Mar; 40(6):1005-17. PubMed ID: 9083491
[TBL] [Abstract][Full Text] [Related]
12. Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A.
Currens MJ; Mariner JM; McMahon JB; Boyd MR
J Pharmacol Exp Ther; 1996 Nov; 279(2):652-61. PubMed ID: 8930168
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
14. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
15. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
16. [Anti-HIV activities of HIV-1 reverse transcriptase inhibitor racemic 11-demethyl-calanolide A].
Peng ZG; Chen HS; Wang L; Liu G
Yao Xue Xue Bao; 2008 May; 43(5):456-60. PubMed ID: 18717330
[TBL] [Abstract][Full Text] [Related]
17. Naturally Occurring Calanolides: Occurrence, Biosynthesis, and Pharmacological Properties Including Therapeutic Potential.
Nahar L; Talukdar AD; Nath D; Nath S; Mehan A; Ismail FMD; Sarker SD
Molecules; 2020 Oct; 25(21):. PubMed ID: 33126458
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis.
Xu ZQ; Barrow WW; Suling WJ; Westbrook L; Barrow E; Lin YM; Flavin MT
Bioorg Med Chem; 2004 Mar; 12(5):1199-207. PubMed ID: 14980631
[TBL] [Abstract][Full Text] [Related]
20. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
